We are live on
!
Find out more
NLVP
New Leaf Venture Partners Portfolio holdings
AUM
$43M
1-Year Est. Return
25.55%
This Fund
S&P 500
This Quarter
Est. Return
+7.32%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$390M
AUM Growth
-$40.1M
(-9.3%)
Cap. Flow
-$4.37M
Cap. Flow
% of AUM
-1.12%
Top 10 Holdings %
Top 10 Hldgs %
93.55%
Holding
19
New
1
Increased
–
Reduced
1
Closed
–
Avg Time Held
10.1
quarters
Top 10 Avg Time Held
5
quarters
Top 20 Avg Time Held
10.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Addex Therapeutics
ADXN
|
+$508K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$4.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Arvinas
ARVN
$500M
| $170M | 43.73% |
2,212,748
-70,300
| -3% | -$4.88M |
2018 Q3
11 quarters
|
|
2
DELISTED
Crinetics Pharmaceuticals
CRNX
| $44.3M | 11.37% |
141,000
| – | – |
2018 Q3
11 quarters
|
|
3
Edgewise Therapeutics
EWTX
$4.24B
| $43.8M | 11.24% |
1,553,661
| – | – |
2021 Q1
1 quarter
|
|
4
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $33.1M | 8.51% |
1,209,571
| – | – |
2017 Q3
15 quarters
|
|
|
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $33.1M | 8.49% |
900,501
| – | – |
2017 Q1
17 quarters
|
|
6
DELISTED
Chimerix, Inc.
CMRX
| $9.8M | 2.51% |
1,224,600
| – | – |
2018 Q3
11 quarters
|
|
|
APTX
7
DELISTED
Aptinyx Inc. Common Stock
APTX
| $9.31M | 2.39% |
3,290,079
| – | – |
2018 Q2
12 quarters
|
|
8
PDS Biotechnology
PDSB
$100M
| $7.97M | 2.05% |
117,242
| – | – |
2019 Q2
8 quarters
|
|
9
Alector
ALEC
$232M
| $7.07M | 1.82% |
339,569
| – | – |
2019 Q1
9 quarters
|
|
|
ARAV
10
DELISTED
Aravive, Inc. Common Stock
ARAV
| $5.66M | 1.45% |
946,423
| – | – |
2018 Q2
12 quarters
|
|
|
CHMA
11
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $5.37M | 1.38% |
1,135,700
| – | – |
2019 Q1
9 quarters
|
|
|
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.07M | 1.04% |
409,611
| – | – |
2017 Q1
17 quarters
|
|
|
HARP
13
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $3.36M | 0.86% |
315,670
| – | – |
2019 Q1
9 quarters
|
|
14
Tectonic Therapeutic
TECX
$456M
| $2.81M | 0.72% |
26,296
| – | – |
2018 Q2
12 quarters
|
|
15
DELISTED
Iterum Therapeutics
ITRM
| $2.73M | 0.7% |
97,087
| – | – |
2018 Q2
12 quarters
|
|
16
Cogent Biosciences
COGT
$5.38B
| $2.66M | 0.68% |
501,530
| – | – |
2018 Q1
13 quarters
|
|
17
X4 Pharmaceuticals
XFOR
$289M
| $2.18M | 0.56% |
11,167
| – | – |
2019 Q2
8 quarters
|
|
18
Passage Bio
PASG
$11.9M
| $1.47M | 0.38% |
124,896
| – | – |
2020 Q1
5 quarters
|
|
|
19
Addex Therapeutics
ADXN
$5.64M
| $478K | 0.12% |
+2,500
| New | +$508K |
2021 Q2
0 quarters
|
|
Similar funds
BAM
MAM
WCPI
WAMC
CC
CIEP
IPI
VSAM
New Leaf Venture Partners's Q2 2021 Portfolio in Review
As of Q2 2021, New Leaf Venture Partners held 19 positions worth $390M, down 9.3% from $430M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
New Leaf Venture Partners's Q2 2021 filing shows 1 new and 1 reduced positions. Its largest new stake was Addex Therapeutics: 2,500 shares worth $478K. The largest sale was Arvinas, an estimated $4.88M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- New Leaf Venture Partners's largest Q2 2021 buy was Addex Therapeutics: 2,500 shares worth $478K.
- New Leaf Venture Partners's biggest Q2 2021 reduction was Arvinas, cutting an estimated $4.88M.
- New Leaf Venture Partners's ten largest holdings make up 94% of its $390M portfolio in Q2 2021.
- New Leaf Venture Partners opened 1 new position and closed 0 in Q2 2021.
- New Leaf Venture Partners's portfolio value fell 9.3% quarter-over-quarter to $390M.
Based on New Leaf Venture Partners's 13F filing for Q2 2021, filed 12 Aug 2021.